# Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC

> **NCT04116918** · — · UNKNOWN · sponsor: **Baodong Qin** · enrollment: 100 (estimated)

## Conditions studied

- NSCLC Stage IV
- EGFR T790M-negative
- Anlotinib
- JS001

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04116918
- **Lead sponsor:** Baodong Qin
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2019-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04116918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04116918, "Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04116918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*